Private Payers Beginning To Adopt ASP-Based Reimbursement, Amgen Says
Private payers are beginning to adopt Medicare's average sales price-based methodology for drugs administered in the physician's office, Amgen said during a quarterly earnings call April 19
You may also be interested in...
Increasing competition could negatively impact market potential for biotech products, Merrill Lynch's David Munno suggested
Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011